News & Research - HBM Partners AG

Important legal information

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Adrenomed closes € 24 M financing led by Wellington and HBM (152 KB)
26.11.2018
Download
TP Therapeutics Raises $80 Million for Targeted Cancer Therapies (1195 KB)
19.10.2018
Download
Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168 (23 KB)
16.10.2018
Download
Sphingotec Raises €20 Million from HBM and Wellington Partners (147 KB)
8.10.2018
Download
Paratek Announces FDA Approval of NUZYRA TM (Omadacycline) (1217 KB)
2.10.2018
Download
FDA Approves SEYSARA (Sarecycline) for the Treatment of Moderate to Severe Acne (121 KB)
2.10.2018
Download
Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (57 KB)
25.9.2018
Download
Neurelis Files NDA with the FDA for VALTOCO™ Nasal Spray, an Investigational Treatment for Epilepsy Patients (62 KB)
25.9.2018
Download
Galera Therapeutics Raises $150 Million for Phase III Trial to Reduce Radiotherapy Side Effects (159 KB)
19.9.2018
Download
Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (22 KB)
18.9.2018
Download

<1 2 345 6 >

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more
Der Kampf gegen das Vergessen (561 KB)
4.6.2018
Download Read more
Die Zuversicht für den Biotech-Sektor wächst (328 KB)
18.11.2017
Download Read more
Novartis setzt auf Nuklearmedizin (106 KB)
31.10.2017
Download Read more
Novartis's neue Wette im Krebsgeschäft (1502 KB)
31.10.2017
Download Read more
Trends und Chancen für den Anleger (840 KB)
1.9.2017
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Important legal information

Adrenomed closes € 24 M financing led by Wellington and HBM (152 KB)

TP Therapeutics Raises $80 Million for Targeted Cancer Therapies (1195 KB)

Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168 (23 KB)

Sphingotec Raises €20 Million from HBM and Wellington Partners (147 KB)

Paratek Announces FDA Approval of NUZYRA TM (Omadacycline) (1217 KB)

FDA Approves SEYSARA (Sarecycline) for the Treatment of Moderate to Severe Acne (121 KB)

Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (57 KB)

Neurelis Files NDA with the FDA for VALTOCO™ Nasal Spray, an Investigational Treatment for Epilepsy Patients (62 KB)

Galera Therapeutics Raises $150 Million for Phase III Trial to Reduce Radiotherapy Side Effects (159 KB)

Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (22 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Der Kampf gegen das Vergessen (561 KB)

Die Zuversicht für den Biotech-Sektor wächst (328 KB)

Novartis setzt auf Nuklearmedizin (106 KB)

Novartis's neue Wette im Krebsgeschäft (1502 KB)

Trends und Chancen für den Anleger (840 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2018 (1263 KB)

Pharma / Biotech M&A Transactions 2005-2018 (106 KB)